Literature DB >> 11932358

The Influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A).

Miyuki Niimi1, Seiichiro Yamamoto, Haruhiko Fukuda, Naoki Ishizuka, Hideyuki Akaza.   

Abstract

BACKGROUND: Progression-free survival (PFS) is a common endpoint in cancer clinical trials. This study was undertaken to assess the impact of data errors and data handling on the statistical estimation of PFS.
METHODS: Data from four trials conducted by the Japan Clinical Oncology Group were examined. Three types of data handling methods were defined: (1) data handling method A (METHOD-A), the collected event data are used as much as possible, (2) METHOD-C, only reliable data with firm evidence are used, and (3) METHOD-B is intermediate between METHOD-A and METHOD-C. To assess the impact of each of the three methods, Kaplan-Meier survival curves, median PFS, proportion of PFS, log-rank p values and hazard ratios were estimated.
RESULTS: In three trials that collected PFS data periodically, no remarkable differences in median PFS and the proportion of PFS were observed. In one trial with non-periodic data cleaning, however, the ratio of median PFS by METHOD-C to that by METHOD-B was 0.85, the maximum difference of proportion of PFS between METHOD-C and METHOD-B was 12.0% and the largest spread in PFS curves amongst the three methods was observed in this trial. In all trials, log-rank p values and hazard ratios for between arm comparisons did not differ between the three methods.
CONCLUSIONS: Periodic data management can reduce errors in comparisons of PFS and is a critical requirement when using PFS as a major endpoint. Furthermore, proper data handling is essential in the estimation of patient benefit and caution is needed when making clinical decisions based on PFS.

Entities:  

Mesh:

Year:  2002        PMID: 11932358     DOI: 10.1093/jjco/hyf003

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  2 in total

1.  Applying Data Warehousing to a Phase III Clinical Trial From the Fondazione Italiana Linfomi Ensures Superior Data Quality and Improved Assessment of Clinical Outcomes.

Authors:  Gian Maria Zaccaria; Simone Ferrero; Samanta Rosati; Marco Ghislieri; Elisa Genuardi; Andrea Evangelista; Rebecca Sandrone; Cristina Castagneri; Daniela Barbero; Mariella Lo Schirico; Luca Arcaini; Anna Lia Molinari; Filippo Ballerini; Andres Ferreri; Paola Omedè; Alberto Zamò; Gabriella Balestra; Mario Boccadoro; Sergio Cortelazzo; Marco Ladetto
Journal:  JCO Clin Cancer Inform       Date:  2019-10

2.  Progression-free survival as a surrogate endpoint in advanced breast cancer.

Authors:  Rebecca A Miksad; Vera Zietemann; Raffaella Gothe; Ruth Schwarzer; Annette Conrads-Frank; Petra Schnell-Inderst; Björn Stollenwerk; Uwe Siebert
Journal:  Int J Technol Assess Health Care       Date:  2008       Impact factor: 2.188

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.